The correct answer is to reduce the spironolactone dose and recheck labs soon. A modest increase in creatinine (<30-35% from baseline) and mild hyperkalemia (5.1-5.5 mEq/L) are expected effects when initiating a mineralocorticoid receptor antagonist (MRA). The appropriate response is to decrease the dose, not stop the medication entirely, as MRAs provide significant mortality benefit. Discontinuing the MRA (A) is overly aggressive. Continuing the same dose (C) without close follow-up is unsafe. Discontinuing the ACE inhibitor (D) is incorrect; the MRA is the newly added agent and should be adjusted first.

Early post-discharge follow-up (within 7-10 days) is a critical component of transitional care for heart failure patients and has the strongest evidence for reducing 30-day readmissions. This visit allows for assessment of volume status, medication adjustment, lab monitoring, and reinforcement of education. While medication access (A), home health services (B), and dietary education (D) are all valuable components of a comprehensive discharge plan, the structured, early physician follow-up is the single most impactful intervention for preventing early readmission.

This patient meets all criteria for CRT-D therapy. He has an LVEF ≤35% despite ≥3 months of optimal GDMT, remains symptomatic (NYHA Class III), is in sinus rhythm, and has a LBBB with a QRS duration ≥150 ms. CRT is indicated to improve symptoms and mortality by correcting ventricular dyssynchrony. An ICD is also indicated for primary prevention of sudden cardiac death. Therefore, a combined CRT-D device is the most appropriate choice. An ICD alone (A) would be insufficient as he also qualifies for CRT. Waiting longer (C) is not indicated as he has had an adequate trial of GDMT. Ivabradine (D) could be considered if his heart rate were ≥70 bpm, but CRT-D is the primary indicated therapy given the wide QRS and LBBB.

This patient has refractory, end-stage (Stage D) heart failure. The most appropriate step is to address the overall trajectory of his illness. This involves a frank discussion about his goals of care (e.g., focus on comfort vs. life extension) and a formal referral to an advanced heart failure center to be evaluated for therapies such as left ventricular assist device (LVAD) or heart transplantation. While IV diuretics (A), digoxin (C), or home inotropes (D) might be used as palliative or bridging measures, they do not address the fundamental need for a higher level of care or shared decision-making about the patient's long-term goals.

This patient has iron deficiency anemia (ferritin <100 ng/mL or ferritin 100-300 ng/mL with TSAT <20%), a common comorbidity in heart failure. In symptomatic HF patients with iron deficiency, intravenous iron repletion has been shown to improve symptoms, functional capacity, and quality of life. Oral iron (A) is often poorly absorbed and tolerated in HF patients due to gut edema and inflammation. Erythropoiesis-stimulating agents (C) have been associated with harm in this population and are not recommended. Transfusion (D) is reserved for acute hemodynamic instability or severe symptoms, not for chronic stable anemia at this level.

When a patient on an angiotensin receptor-neprilysin inhibitor (ARNI) develops symptomatic hypotension, the preferred initial strategy is often to reduce the dose of the ARNI or other vasodilating agents. Since the ARNI was the most recently adjusted medication, reducing its dose is a logical first step. Decreasing the beta-blocker (B) is another option, but ARNIs have a more potent blood pressure lowering effect. Discontinuing the diuretic (C) may be considered if there are clear signs of volume depletion, but lightheadedness is a direct effect of vasodilation. Switching back to an ACEi/ARB (D) is not necessary unless the ARNI is not tolerated even at the lowest dose, as it provides superior outcomes.

When managing patients with heart failure, you must balance ongoing cardiac care with essential preventive measures. This question tests your understanding of vaccination priorities in vulnerable populations during flu season.

The correct answer is D because annual influenza vaccination is critically important for patients with heart failure. Influenza can trigger acute decompensation in HFrEF patients, leading to hospitalizations and increased mortality. Since this visit occurs in October—peak flu vaccination season—this intervention takes priority. The CDC specifically recommends annual flu vaccines for all patients with cardiovascular disease as a high-priority preventive measure.

Choice A is incorrect because screening colonoscopy, while important for this age group, is not time-sensitive like seasonal vaccinations and doesn't directly impact his heart failure prognosis in the immediate term.

Choice B represents a valuable intervention since pneumococcal disease poses significant risks to heart failure patients, but it's not seasonal and can be administered at subsequent visits without losing efficacy.

Choice C, while recommended for adults over 60, is similarly non-urgent. Zoster vaccination provides important protection but doesn't carry the same immediate seasonal timing requirements or direct cardiovascular risk implications as influenza vaccination.

Remember that USMLE Step 3 often tests clinical prioritization in real-world scenarios. When you see heart failure patients during flu season, think "influenza vaccination first." The combination of increased infection risk, potential for cardiac decompensation, and seasonal timing makes this the highest-yield preventive intervention at this specific visit.

In patients with atrial fibrillation and heart failure, the single most important intervention to prevent major adverse events (specifically stroke) is therapeutic anticoagulation. Given her CHA₂DS₂-VASc score of 5, her risk of stroke is high, and anticoagulation is mandatory unless contraindicated. While rate control (B) is important for symptom management and preventing tachycardia-mediated cardiomyopathy, and rhythm control strategies (A, D) may be considered, neither has been consistently shown to be superior to rate control for mortality benefit, and they do not replace the need for stroke prevention with anticoagulation.

Asymptomatic, non-sustained VT that does not trigger ICD therapy does not require specific treatment. The purpose of the ICD is to treat life-threatening sustained arrhythmias, and its detection of NSVT shows it is monitoring correctly. Adding empiric amiodarone (A) is not indicated for asymptomatic NSVT and would expose the patient to significant potential toxicity. The patient is already on an optimal dose of carvedilol (C), and further increases may not be tolerated. Ablation (D) is reserved for patients with recurrent symptomatic VT or frequent ICD shocks despite medical therapy.

When you encounter a patient with symptoms suggestive of depression, especially in the context of chronic illness, the first step is always objective assessment before initiating treatment. This question tests your understanding of the systematic approach to diagnosing depression in primary care.

The correct approach is option D - administering a validated screening tool like the PHQ-9. This patient presents with classic depressive symptoms: anhedonia (loss of interest), hopelessness, sleep disturbance, and appetite changes lasting over a month. However, before making any therapeutic decisions, you need to establish the severity and confirm the diagnosis using standardized criteria. The PHQ-9 provides objective scoring that guides treatment decisions and establishes baseline severity for monitoring response.

Option A is premature - while SSRIs like sertraline are appropriate first-line treatments for depression in heart failure patients, you shouldn't start antidepressants without first confirming the diagnosis and assessing severity. Option B represents unnecessary escalation - primary care physicians are fully capable of managing depression, and immediate psychiatric referral isn't indicated unless there are suicidal ideations or treatment-resistant cases. Option C is both dismissive and incorrect - while depression is more common in chronic illness, it's never "normal" and always warrants evaluation and treatment.

For USMLE Step 3, remember that clinical decision-making questions often test your ability to follow proper diagnostic sequences. When symptoms suggest a psychiatric condition, always screen and assess objectively before treating. The pattern is: recognize symptoms → validate with screening tools → then treat based on results.